Compare UTI & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTI | ELVN |
|---|---|---|
| Founded | 1965 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | 2003 | 2020 |
| Metric | UTI | ELVN |
|---|---|---|
| Price | $34.40 | $30.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $37.50 | ★ $41.00 |
| AVG Volume (30 Days) | ★ 910.4K | 575.0K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.67 | 3.17 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $835,616,000.00 | N/A |
| Revenue This Year | $10.15 | N/A |
| Revenue Next Year | $8.23 | $40.06 |
| P/E Ratio | $149.26 | ★ N/A |
| Revenue Growth | ★ 14.05 | N/A |
| 52 Week Low | $21.29 | $13.30 |
| 52 Week High | $38.02 | $30.78 |
| Indicator | UTI | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 59.08 | 66.58 |
| Support Level | $30.22 | $18.51 |
| Resistance Level | $35.47 | N/A |
| Average True Range (ATR) | 1.62 | 1.43 |
| MACD | -0.16 | 0.03 |
| Stochastic Oscillator | 56.13 | 96.65 |
Universal Technical Institute Inc is an educational institution. It provides undergraduate degree, as well as certificate programs for technicians in the automotive, diesel, collision repair, motorcycle and marine fields. The company's reportable segment which includes Universal Technical Institute (UTI) and Concorde Career Colleges, Corporate. Majority of the revenue is generated from UTI segment which provides different kinds of degree and non-degree transportation and skilled trades technical training programs under brands such as Universal Technical Institute, Motorcycle Mechanics Institute, Marine Mechanics Institute and others. It also provides dealer technician training or instructor staffing services to manufacturers.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.